EMEA-002299-PIP01-17

Key facts

Active substance
Enfortumab vedotin
Therapeutic area
Oncology
Decision number
P/0114/2018
PIP number
EMEA-002299-PIP01-17
Pharmaceutical form(s)
Powder and solvent for solution for infusion
Condition(s) / indication(s)
Treatment of urothelial carcinoma
Route(s) of administration
Intravenous use
Contact for public enquiries
Astellas Pharma Europe B.V.
Tel.: +31 715455878
e-mail: contact@nl.astellas.com
Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

How useful was this page?

Add your rating